-+ 0.00%
-+ 0.00%
-+ 0.00%
Nasus Pharma CFO Eyal Rubin to exit; finance director Oren Elmaliach named interim CFO
Share
Listen to the news
Nasus Pharma CFO Eyal Rubin to exit; finance director Oren Elmaliach named interim CFO
  • Nasus Pharma CFO Eyal Rubin will leave to pursue an opportunity outside the life sciences industry.
  • Rubin will remain through Sept. 18, 2026 to support an orderly transition.
  • Director of Finance Oren Elmaliach was appointed interim CFO.
  • Elmaliach has been with Nasus since inception; a CPA with 15+ years’ finance experience across public and private life sciences companies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190700PRIMZONEFULLFEED9812526) on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending